Lutherstadt Wittenberg

This study evaluates the long-term safety and tolerability of pelacarsen TQJ230 in people with established cardiovascular disease and elevated Lipoproteina who completed a previous related study. It is an open-label extension trial, meaning all participants receive the study drug without placebo comparison. The trial is sponsored by Novartis Pharmaceuticals and focuses on continued treatment after the completion of the parent study. Participants receive monthly injections of pelacarsen 80 mg subcutaneously for up to 36 months during this extension phase. This phase is designed to provide access to the study drug after the initial trial and to monitor participants closely. The study does not involve randomization or blinding, and all enrolled participants receive the active drug. During the study, participants will undergo regular assessments including monitoring for adverse events and cardiovascular events, as well as measuring Lipoproteina levels at baseline and several time points over 36 months. Safety and tolerability will be closely tracked throughout the treatment period. The total duration of participation corresponds to the length of the extension phase, up to three years.

This research aims to reduce suffering in intensive care units by studying palliative care consultations. It evaluates how effective and cost-efficient these consultations are for ICU patients, implementing a Europe-wide recommended palliative care practice. The study also includes anonymous surveys of doctors and nurses during both intervention and control phases across multiple centers. Participants in the intervention group will receive a complex approach including telemedical consultations by specialized palliative care experts, training for ICU staff in basic palliative care, and use of checklists to identify patients needing palliative care early. The control group will receive routine ICU treatment without these additional interventions. The study uses a cluster-randomized controlled design to assess the impact of these practices. During their ICU stay, patients will be monitored for length of stay, costs, symptom presence, organ failure scores, readmissions, and use of medical resources. Follow-ups extend up to three months to assess outcomes such as mortality, quality of life, communication satisfaction, and resource use. Staff and relatives will also be surveyed about care quality and experiences. The total observation period for some measures extends up to 34 months to evaluate long-term effects and ethical aspects of care.